07:50 AM EDT, 06/11/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Wednesday appointment Jared Kelly as chief executive officer and a member of its board.

Kelly is a biotech executive who most recently was involved in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for US$2 billion, a statement noted.

"We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors," said Oncolytics Chair Wayne Pisano, who is also the outgoing interim chief executive.